A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

Launch of Promising Late-stage Anti-hypertensive Drugs to Drive Growth of Branded ACS Therapeutics

RELEASE DATE
20-May-2015
REGION
Global
Research Code: MB06-01-00-00-00
SKU: LS00109-GL-MR_16950
AvailableYesPDF Download
$3,950.00
In stock
SKU
LS00109-GL-MR_16950
$3,950.00
DownloadLink
ENQUIRE NOW

Description

This research service offers an assessment for marketed and pipeline products for the global ACS therapeutics market. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into anti-platelet therapeutics, anti-hypertensives and cholesterol lowering drugs, anti-thrombins, and others. Other upcoming therapies include anti-inflammatories. The forecast period is 2015–2025.

Table of Contents

Executive Summary—Key Findings

Executive Summary—Key Findings (continued)

Key Trends

Companies to Watch

Methodology and Scope

Market Overview—Introduction

Market Overview—Epidemiology

Market Overview—Epidemiology (continued)

Market Overview—Epidemiology (continued)

Physicians Treatment Guidelines

Physicians Treatment Guidelines (continued)

Physicians Treatment Guidelines (continued)

Physicians Treatment Guidelines (continued)

Market Size

Market Size—Segmentation

Market Forecast

Market Segmentation

Competitive Landscape Overview

Competitive Landscape—Marketed and Pipeline Products

Marketed Products—Anti-platelet Therapy

Pipeline Products—Anti-platelet Therapy

Marketed Products—Anti-thrombin Therapy

Marketed Products—Anti-thrombin Therapy (continued)

Pipeline Products—Anti-thrombin Therapy

Marketed Products—Anti-hypertensives & Cholesterol Lowering Drugs

Marketed Products—Anti-hypertensives & Cholesterol Lowering Drugs (continued)

Pipeline Products—Anti-hypertensives & Cholesterol Lowering Drugs

Pipeline Products—Others

Product Launch Timeline

Patent Expirations

ACS Therapeutics—Major Ongoing/Recently Completed Clinical Trials

ACS Therapeutics—Major Ongoing/Recently Completed Clinical Trials (continued)

Summary of Key Products to Watch

Product Dashboard: Plavix (clopidogrel)—Bristol-Myers Squibb

Product Dashboard: Brilinta (ticagrelor)—The Medicines Company

Product Dashboard: Angiomax—The Medicines Company

Product Dashboard: Zocor (simvastatin)—Merck

Product Dashboard: Xarelto (rivaroxaban)—Bayer

Product Dashboard: Alirocumab (RGN727)—Sanofi & Regeneron

Product Dashboard: Evolocumab (Repatha)—Amgen

Product Dashboard: Evacetrapib—Eli Lilly & Company

Product Dashboard: Losmapimod—GSK

Conclusions

Legal Disclaimer

Decision Support Database

Decision Support Database (continued)

Decision Support Database (continued)

Decision Support Database (continued)

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
China is predicted to become the third-largest pharmaceutical market in the world by the end of 2013 due to the governments considerable investment in the healthcare industry and the populations unmet healthcare needs. The life sciences industry is broad and involves a wide range of disciplines. This research service focuses on the trends and market opportunities in Chinas life sciences industrythe regulatory environment, the registration pathway of various drugs and IVD products, and M&A. Medical devices and the related registration pathway are not included. In this study, the base year is 2012, and the forecast period runs 20132017. An analysis of market challenges, drivers, and restraints impacting industry growth are provided.
More Information
No Index No
Podcast No
Author Sriram Radhakrishnan
WIP Number MB06-01-00-00-00
Is Prebook No